TR
Trevi Therapeutics, Inc.
TRVI · NASDAQ
$16.64 -1.51% (-$0.25)
1M -6.52%
Market Cap $2.36B
P/E Ratio -
Div. Yield -
ROE 23.59%
Bulios Fair Price
$10.95
34.2% downside
Trenutna cena
$16.64
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica TRVI trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
1/9Valuation
8 /100
Expensive P/B 7.35x
P/E N/A
P/FFO N/A
Growth
100 /100
Growing Book val. growth 19.47%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 18.46%
Asset turnover 0.00x
ROE 23.59%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 37.28x
Int. coverage N/A
Stability
43 /100
Moderate Beta 1.05x
Profitable years 0
EPS volatility 57.17%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o TRVI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jennifer L. Good
Employees
34
Headquarters
New Haven
Prihajajoči dogodki
12 NOV.
Earnings
Upcoming earnings report